Literature DB >> 24123308

Characterization of human paraoxonase 1 variants suggest that His residues at 115 and 134 positions are not always needed for the lactonase/arylesterase activities of the enzyme.

Priyanka Bajaj1, Rajan K Tripathy, Geetika Aggarwal, Abhay H Pande.   

Abstract

Human paraoxonase 1 (h-PON1) hydrolyzes variety of substrates and the hydrolytic activities of enzyme can be broadly grouped into three categories; arylesterase, phosphotriesterase, and lactonase. Current models of the catalytic mechanism of h-PON1 suggest that catalytic residues H115 and H134 mediate the lactonase and arylesterase activities of the enzyme. H-PON1 is a strong candidate for the development of catalytic bioscavenger for organophosphate poisoning in humans. Recently, Gupta et al. (Nat. Chem. Biol. 2011. 7, 120) identified amino acid substitutions that significantly increased the activity of chimeric-PON1 variant (4E9) against some organophosphate nerve agents. In this study we have examined the effect of these (L69G/S111T/H115W/H134R/R192K/F222S/T332S) and other substitutions (H115W/H134R and H115W/H134R/R192K) on the hydrolytic activities of recombinant h-PON1 (rh-PON1) variants. Our results show that the substitutions resulted in a significant increase in the organophosphatase activity of all the three variants of rh-PON1 enzyme while had a variable effect on the lactonase/arylesterase activities. The results suggest that H residues at positions 115 and 134 are not always needed for the lactonase/arylesterase activities of h-PON1 and force a reconsideration of the current model(s) of the catalytic mechanism of h-PON1.
© 2013 The Protein Society.

Entities:  

Keywords:  acyl homoserine lactone; organophosphate; recombinant human PON1; site directed mutagenesis

Mesh:

Substances:

Year:  2013        PMID: 24123308      PMCID: PMC3843633          DOI: 10.1002/pro.2380

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  37 in total

1.  Structural characterization of the catalytic calcium-binding site in diisopropyl fluorophosphatase (DFPase)--comparison with related beta-propeller enzymes.

Authors:  Marc-Michael Blum; Julian C-H Chen
Journal:  Chem Biol Interact       Date:  2010-03-03       Impact factor: 5.192

2.  Calcium-dependent human serum homocysteine thiolactone hydrolase. A protective mechanism against protein N-homocysteinylation.

Authors:  H Jakubowski
Journal:  J Biol Chem       Date:  2000-02-11       Impact factor: 5.157

3.  Directed evolution of hydrolases for prevention of G-type nerve agent intoxication.

Authors:  Rinkoo D Gupta; Moshe Goldsmith; Yacov Ashani; Yair Simo; Gavriel Mullokandov; Hagit Bar; Moshe Ben-David; Haim Leader; Raanan Margalit; Israel Silman; Joel L Sussman; Dan S Tawfik
Journal:  Nat Chem Biol       Date:  2011-01-09       Impact factor: 15.040

Review 4.  Human paraoxonase: a promising approach for pre-treatment and therapy of organophosphorus poisoning.

Authors:  Daniel Rochu; Eric Chabrière; Patrick Masson
Journal:  Toxicology       Date:  2006-09-03       Impact factor: 4.221

5.  Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters.

Authors:  S Billecke; D Draganov; R Counsell; P Stetson; C Watson; C Hsu; B N La Du
Journal:  Drug Metab Dispos       Date:  2000-11       Impact factor: 3.922

6.  In silico analyses of substrate interactions with human serum paraoxonase 1.

Authors:  Xin Hu; Xiaohui Jiang; David E Lenz; Douglas M Cerasoli; Anders Wallqvist
Journal:  Proteins       Date:  2009-05-01

Review 7.  Pharmacogenetics of paraoxonases: a brief review.

Authors:  D I Draganov; B N La Du
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-10-25       Impact factor: 3.000

8.  Stability of highly purified human paraoxonase (PON1): association with human phosphate binding protein (HPBP) is essential for preserving its active conformation(s).

Authors:  Daniel Rochu; Frédérique Renault; Cécile Cléry-Barraud; Eric Chabrière; Patrick Masson
Journal:  Biochim Biophys Acta       Date:  2007-05-22

9.  Engineered recombinant human paraoxonase 1 (rHuPON1) purified from Escherichia coli protects against organophosphate poisoning.

Authors:  Richard C Stevens; Stephanie M Suzuki; Toby B Cole; Sarah S Park; Rebecca J Richter; Clement E Furlong
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-18       Impact factor: 11.205

10.  Solubilization and humanization of paraoxonase-1.

Authors:  Mohosin Sarkar; Christina Keventzidis Harsch; George T Matic; Kathryn Hoffman; Joseph R Norris; Tamara C Otto; David E Lenz; Douglas M Cerasoli; Thomas J Magliery
Journal:  J Lipids       Date:  2012-06-07
View more
  4 in total

Review 1.  Organophosphate-Hydrolyzing Enzymes as First-Line of Defence Against Nerve Agent-Poisoning: Perspectives and the Road Ahead.

Authors:  A R Satvik Iyengar; Abhay H Pande
Journal:  Protein J       Date:  2016-12       Impact factor: 2.371

Review 2.  Human paraoxonase 1 as a pharmacologic agent: limitations and perspectives.

Authors:  Priyanka Bajaj; Rajan K Tripathy; Geetika Aggarwal; Abhay H Pande
Journal:  ScientificWorldJournal       Date:  2014-10-20

3.  Toward Understanding the Catalytic Mechanism of Human Paraoxonase 1: Site-Specific Mutagenesis at Position 192.

Authors:  Geetika Aggarwal; Rameshwar Prajapati; Rajan K Tripathy; Priyanka Bajaj; A R Satvik Iyengar; Abhay T Sangamwar; Abhay H Pande
Journal:  PLoS One       Date:  2016-02-01       Impact factor: 3.240

Review 4.  Enzymatic Bioremediation of Organophosphate Compounds-Progress and Remaining Challenges.

Authors:  Meghna Thakur; Igor L Medintz; Scott A Walper
Journal:  Front Bioeng Biotechnol       Date:  2019-11-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.